Jeremy Rees
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeremy Rees has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Harpreet Hyare
Department of Translational Neuroscience and Stroke, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London
2 shared publications Ajay Aggarwal
A National Hospital for Neurology and Neurosurgery , Queen Square, London , UK
1 shared publication- Ashirwad Merve
Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
1 shared publication Diana Caine
Department of Neuropsychology National Hospital for Neurology and Neurosurgery London UK
1 shared publication- Elizabeth Vacher
UCL Medical School, London, UK
1 shared publication Garth Cruickshank
Neurosurgery, Queen Elizabeth Hospital Birmingham, Birmingham, UK
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (5)
Management of epilepsy in the brain tumour patient: Current concepts and practical approaches
- 28 September 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (5)
Open AccessManagement of epilepsy in the brain tumour patient: Current concepts and practical approaches
- Open Access
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii19
MATHEMATICAL MODELLING OF SURVIVAL IN LOW GRADE GLIOMAS AT MALIGNANT TRANSFORMATION
Low grade gliomas (LGG) represent 14.6% of gliomas and may remain stable years after initial diagnosis. MRI features suggesting malignant transformation (MT) include enlargement of non-enhancing areas and increasing enhancement but have low specificity. We report the first stages of a deep learning model to predict survival using radiomic feature extraction at MT, clinical and molecular genetics. Retrospective analysis of all LGGs treated at our institution (2005 - 2020) with histology, molecular genetics and MRIs. 766 patients: 457 IDH mutant astrocytomas, 251 IDH mutant 1p19q co-deleted oligodendrogliomas and 58 other gliomas; 398 male, 368 female; mean age 51 years; range 16-89. MRIs underwent in-house tumour segmentation pipeline with radiomic feature extraction of whole tumour (wt), enhancing (enh), non-enhancing (ne) component and oedema components. At MT, mean wt volume was 36404mm3 (SD 37213mm3) with mean 2D-diameter of 75.90mm (SD 27.23mm). Mean tissue compartmental volumes: enh 9539mm3 (SD 17578mm3), ne 26865mm3 (SD 33796mm3), and oedema 61067mm3 (SD 61535 mm3). 92 lesions contained no post-contrast enhancing tissue. Lesions were more commonly frontal or temporally based, with relative sparing of parietal and occipital lobes. No predilection for left or right hemisphere. Majority of LGGs demonstrate contrast enhancing lesions at MT in a frontal or temporal spatial distribution with no hemispheric predilection. We plan to extract the MRI features at MT to build a survival model with clinical, treatment and molecular genetic data. Defining the radiological features at MT would enable prognostication and support clinical decision-making in this patient group.
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii19
Open AccessMATHEMATICAL MODELLING OF SURVIVAL IN LOW GRADE GLIOMAS AT MALIGNANT TRANSFORMATION
Low grade gliomas (LGG) represent 14.6% of gliomas and may remain stable years after initial diagnosis. MRI features suggesting malignant transformation (MT) include enlargement of non-enhancing areas and increasing enhancement but have low specificity. We report the first stages of a deep learning model to predict survival using radiomic feature extraction at MT, clinical and molecular genetics. Retrospective analysis of all LGGs treated at our institution (2005 - 2020) with histology, molecular genetics and MRIs. 766 patients: 457 IDH mutant astrocytomas, 251 IDH mutant 1p19q co-deleted oligodendrogliomas and 58 other gliomas; 398 male, 368 female; mean age 51 years; range 16-89. MRIs underwent in-house tumour segmentation pipeline with radiomic feature extraction of whole tumour (wt), enhancing (enh), non-enhancing (ne) component and oedema components. At MT, mean wt volume was 36404mm3 (SD 37213mm3) with mean 2D-diameter of 75.90mm (SD 27.23mm). Mean tissue compartmental volumes: enh 9539mm3 (SD 17578mm3), ne 26865mm3 (SD 33796mm3), and oedema 61067mm3 (SD 61535 mm3). 92 lesions contained no post-contrast enhancing tissue. Lesions were more commonly frontal or temporally based, with relative sparing of parietal and occipital lobes. No predilection for left or right hemisphere. Majority of LGGs demonstrate contrast enhancing lesions at MT in a frontal or temporal spatial distribution with no hemispheric predilection. We plan to extract the MRI features at MT to build a survival model with clinical, treatment and molecular genetic data. Defining the radiological features at MT would enable prognostication and support clinical decision-making in this patient group.
- Open Access
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii18
ADULT HISTONE G34 MUTANT GLIOMAS - A SINGLE CENTRE EXPERIENCE OVER 10 YEARS
Histone G-34-mutant (H3 G34) gliomas are rare, aggressive infiltrating tumours of the cerebral hemispheres and are classified as WHO grade 4 paediatric type diffuse high-grade glioma. They most commonly affect children and adolescents. We describe the clinicopathological characteristics of adult H3 G34-mutant gliomas seen at the National Hospital for Neurology and Neurosurgery over the last 10 years. We retrospectively analyzed clinic radiological data on all cases identified from the neuropathology database. Data were extracted on patient demographics, clinical and radiological features and outcome. Six patients (2 male, 4 female) were identified, The median age of onset was 26 years (range 17-38 years). One patient presented with a Motor Neurone Disease type syndrome (progressive asymmetric spastic tetraparesis and bulbar symptoms), two with cognitive decline and three with symptoms of raised intracranial pressure. All tumours were supratentorial - 2 patients had mass lesions typical of a high-grade glioma, 1 patient had imaging features consistent with an intraventricular ependymoma. 3 patients had imaging findings that suggested a non-tumour diagnosis with extensive white matter disease more in keeping with an inflammatory demyelinating process or a leucodystrophy. The median overall survival was 23 Months (range 10 - 68 months). Adult Histone G34-mutant gliomas have a variable presentation and are associated with a prognosis similar to other high-grade gliomas. The diagnosis should be considered in the differential of patients presenting with a predominantly white matter disorder. Multi-centre studies are needed to better delineate the phenotype and prognostic features.
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii18
Open AccessADULT HISTONE G34 MUTANT GLIOMAS - A SINGLE CENTRE EXPERIENCE OVER 10 YEARS
Histone G-34-mutant (H3 G34) gliomas are rare, aggressive infiltrating tumours of the cerebral hemispheres and are classified as WHO grade 4 paediatric type diffuse high-grade glioma. They most commonly affect children and adolescents. We describe the clinicopathological characteristics of adult H3 G34-mutant gliomas seen at the National Hospital for Neurology and Neurosurgery over the last 10 years. We retrospectively analyzed clinic radiological data on all cases identified from the neuropathology database. Data were extracted on patient demographics, clinical and radiological features and outcome. Six patients (2 male, 4 female) were identified, The median age of onset was 26 years (range 17-38 years). One patient presented with a Motor Neurone Disease type syndrome (progressive asymmetric spastic tetraparesis and bulbar symptoms), two with cognitive decline and three with symptoms of raised intracranial pressure. All tumours were supratentorial - 2 patients had mass lesions typical of a high-grade glioma, 1 patient had imaging features consistent with an intraventricular ependymoma. 3 patients had imaging findings that suggested a non-tumour diagnosis with extensive white matter disease more in keeping with an inflammatory demyelinating process or a leucodystrophy. The median overall survival was 23 Months (range 10 - 68 months). Adult Histone G34-mutant gliomas have a variable presentation and are associated with a prognosis similar to other high-grade gliomas. The diagnosis should be considered in the differential of patients presenting with a predominantly white matter disorder. Multi-centre studies are needed to better delineate the phenotype and prognostic features.
- 2 January 2023
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 39 (1) , 4-11
Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations
Brain Tumour Related Epilepsy (BTRE) has a significant impact on Quality of Life with implications for driving, employment, and social activities. Management of BTRE is complex due to the higher incidence of drug resistance and the potential for interaction between anti-cancer therapy and anti-seizure medications (ASMs). Neurologists, neurosurgeons, oncologists, palliative care physicians and clinical nurse specialists treating these patients would benefit from up-to-date clinical guidelines. We aim to review the current literature and to outline specific recommendations for the optimal treatment of BTRE, encompassing both Primary Brain Tumours (PBT) and Brain Metastases (BM). A comprehensive search of the literature since 2000 on BTRE was carried out in PubMed, MEDLINE and EMCARE. A broad search strategy was used, and the evidence evaluated and graded based on the Oxford Centre for Evidence-Based Medicine Levels of Evidence. Seizure frequency varies between 10 and 40% in patients with Brain Metastases (BM) and from 30% (high-grade gliomas) to 90% (low-grade gliomas) in patients with PBT. In patients with BM, risk factors include number of BM and melanoma histology. In patients with PBT, BTRE is more common in patients with lower grade histology, frontal and temporal tumours, presence of an IDH mutation and cortical infiltration. All patients with BTRE should be treated with ASMs. Non-enzyme inducing ASMs are recommended as first line treatment for BTRE, but up to 50% of patients with BTRE due to PBT remain resistant. There is no proven benefit for the use of prophylactic ASMs, although there are no randomised trials testing newer agents. Surgical and oncological treatments i.e. radiotherapy and chemotherapy improve BTRE. Vagus Nerve Stimulation has been used with partial success. The review highlights the relative dearth of high-quality evidence for the management of BTRE and provides a framework for further studies aiming to improve seizure control, quality of life, and indications for ASMs.
- 2 January 2023
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 39 (1) , 4-11
Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations
Brain Tumour Related Epilepsy (BTRE) has a significant impact on Quality of Life with implications for driving, employment, and social activities. Management of BTRE is complex due to the higher incidence of drug resistance and the potential for interaction between anti-cancer therapy and anti-seizure medications (ASMs). Neurologists, neurosurgeons, oncologists, palliative care physicians and clinical nurse specialists treating these patients would benefit from up-to-date clinical guidelines. We aim to review the current literature and to outline specific recommendations for the optimal treatment of BTRE, encompassing both Primary Brain Tumours (PBT) and Brain Metastases (BM). A comprehensive search of the literature since 2000 on BTRE was carried out in PubMed, MEDLINE and EMCARE. A broad search strategy was used, and the evidence evaluated and graded based on the Oxford Centre for Evidence-Based Medicine Levels of Evidence. Seizure frequency varies between 10 and 40% in patients with Brain Metastases (BM) and from 30% (high-grade gliomas) to 90% (low-grade gliomas) in patients with PBT. In patients with BM, risk factors include number of BM and melanoma histology. In patients with PBT, BTRE is more common in patients with lower grade histology, frontal and temporal tumours, presence of an IDH mutation and cortical infiltration. All patients with BTRE should be treated with ASMs. Non-enzyme inducing ASMs are recommended as first line treatment for BTRE, but up to 50% of patients with BTRE due to PBT remain resistant. There is no proven benefit for the use of prophylactic ASMs, although there are no randomised trials testing newer agents. Surgical and oncological treatments i.e. radiotherapy and chemotherapy improve BTRE. Vagus Nerve Stimulation has been used with partial success. The review highlights the relative dearth of high-quality evidence for the management of BTRE and provides a framework for further studies aiming to improve seizure control, quality of life, and indications for ASMs.
- 22 August 2022
- Published by BMJ in Practical Neurology
- Vol. 22 (6) , 450-460
Radiation and the nervous system
Radiation therapy is widely used for benign and malignant brain tumours as it is effective and well tolerated. However, damage to the surrounding healthy nervous system tissue leads to a variety of complications both in the short term and long term, ranging from mild and self-limiting to irreversible and fatal. Radiation neurotoxicity is due to a combination of early inflammation and oligodendroglial damage followed later by brain tissue necrosis, white matter damage, accelerated vascular disease and the development of secondary tumours. This article explains the basic principles of radiation physics, the different modalities used in clinical practice, how radiotherapy is planned and delivered and the scientific basis of radiation damage. The main body of the article focuses on the clinical features of radiation toxicity in the brain, spinal cord, cranial and peripheral nerves with an emphasis on the distinction between early and delayed complications.
- 22 August 2022
- Published by BMJ in Practical Neurology
- Vol. 22 (6) , 450-460
Radiation and the nervous system
Radiation therapy is widely used for benign and malignant brain tumours as it is effective and well tolerated. However, damage to the surrounding healthy nervous system tissue leads to a variety of complications both in the short term and long term, ranging from mild and self-limiting to irreversible and fatal. Radiation neurotoxicity is due to a combination of early inflammation and oligodendroglial damage followed later by brain tissue necrosis, white matter damage, accelerated vascular disease and the development of secondary tumours. This article explains the basic principles of radiation physics, the different modalities used in clinical practice, how radiotherapy is planned and delivered and the scientific basis of radiation damage. The main body of the article focuses on the clinical features of radiation toxicity in the brain, spinal cord, cranial and peripheral nerves with an emphasis on the distinction between early and delayed complications.
- 17 May 2022
- Published by BMJ in Practical Neurology
- Vol. 22 (4) , 268-273
Eligibility to drive and neurology: the how and the why
Driving is an integral part of adult life and losing a driving licence is potentially a major problem. Many neurological conditions may impact on driving, either by increasing the risk of a sudden disabling event or by affecting cognition, vision, reaction speed, motor coordination, peripheral sensation or visuospatial processing. In the UK, the Drivers Medical Group of the Driver and Vehicle Licensing Agency (DVLA) decides whether an individual’s medical condition meets the appropriate standards for driving. The licensing decision rests with the DVLA and is not at the clinician’s discretion. However, clinicians must inform patients of their legal obligations towards the DVLA and how their neurological symptoms may restrict their driving. We discuss risk assessment, how chronic disabling neurological disease may impact on driving and the general principles of applying medical standards for fitness to drive. We also highlight how legal driving eligibility varies around the world. Finally, we discuss the practical applications relating to a specific case.
- 17 May 2022
- Published by BMJ in Practical Neurology
- Vol. 22 (4) , 268-273
Eligibility to drive and neurology: the how and the why
Driving is an integral part of adult life and losing a driving licence is potentially a major problem. Many neurological conditions may impact on driving, either by increasing the risk of a sudden disabling event or by affecting cognition, vision, reaction speed, motor coordination, peripheral sensation or visuospatial processing. In the UK, the Drivers Medical Group of the Driver and Vehicle Licensing Agency (DVLA) decides whether an individual’s medical condition meets the appropriate standards for driving. The licensing decision rests with the DVLA and is not at the clinician’s discretion. However, clinicians must inform patients of their legal obligations towards the DVLA and how their neurological symptoms may restrict their driving. We discuss risk assessment, how chronic disabling neurological disease may impact on driving and the general principles of applying medical standards for fitness to drive. We also highlight how legal driving eligibility varies around the world. Finally, we discuss the practical applications relating to a specific case.
- Open Access
- 7 February 2022
- Published by Springer Nature
- p. 141-145
Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
A common and challenging side effect associated with CAR-T cell therapy is immune cell-associated neurotoxicity syndrome (ICANS), which occurs in 20–60% of patients, of whom 12–30% have severe (≥ grade 3) symptoms.
- 7 February 2022
- Published by Springer Nature
- p. 141-145
Open AccessManagement of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
A common and challenging side effect associated with CAR-T cell therapy is immune cell-associated neurotoxicity syndrome (ICANS), which occurs in 20–60% of patients, of whom 12–30% have severe (≥ grade 3) symptoms.
- 30 November 2020
- Published by Wiley in Journal of Neuropsychology
- Vol. 15 (3) , 428-447
A case study investigating the role of the anterior temporal lobes in general semantics and semantics specific to persons, emotions and social conceptual knowledge
The role of the anterior temporal lobes (ATLs) in semantic representation remains still much debated. Long thought to support domain‐general semantic processing, recent accounts have alternatively suggested that they may be preferentially involved in the processing of person‐related semantic knowledge. Several studies have supported such a distinction, but few have either examined both types of semantic processing together, or considered the role of potentially important confounding variables. Here, we address these issues by investigating both domain‐general and person‐specific semantic processing in a patient with focal ATL damage. The patient presents with dense anterograde and retrograde amnesia. Performance was impaired on tests of general semantic knowledge, but most striking deficits were for person‐related semantics, including recognition and identification, knowledge of emotions and social conceptual knowledge. This unique case provides compelling evidence that, in addition to the role in general semantic knowledge, the ATLs are critical for person‐related semantics.
- 30 November 2020
- Published by Wiley in Journal of Neuropsychology
- Vol. 15 (3) , 428-447
A case study investigating the role of the anterior temporal lobes in general semantics and semantics specific to persons, emotions and social conceptual knowledge
The role of the anterior temporal lobes (ATLs) in semantic representation remains still much debated. Long thought to support domain‐general semantic processing, recent accounts have alternatively suggested that they may be preferentially involved in the processing of person‐related semantic knowledge. Several studies have supported such a distinction, but few have either examined both types of semantic processing together, or considered the role of potentially important confounding variables. Here, we address these issues by investigating both domain‐general and person‐specific semantic processing in a patient with focal ATL damage. The patient presents with dense anterograde and retrograde amnesia. Performance was impaired on tests of general semantic knowledge, but most striking deficits were for person‐related semantics, including recognition and identification, knowledge of emotions and social conceptual knowledge. This unique case provides compelling evidence that, in addition to the role in general semantic knowledge, the ATLs are critical for person‐related semantics.
- 1 October 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 7 (5) , 578-579
Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better
We enjoyed reading the letter by J. Pallud regarding our paper published in Neuro-Oncology Practice, and thank him for his kind words.
- 1 October 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 7 (5) , 578-579
Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better
We enjoyed reading the letter by J. Pallud regarding our paper published in Neuro-Oncology Practice, and thank him for his kind words.
- Open Access
- 21 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 7 (2) , 196-201
Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better
There has been a trend toward earlier and more aggressive resection for low-grade gliomas (LGGs). This study set out to compare seizure control and survival of adults with LGG seen in the same neuro-oncology clinic over 11 years and to determine whether a change in surgical philosophy has led to a corresponding improvement in outcomes. We conducted a retrospective analysis using case-note review of 153 adults with histologically verified or radiologically suspected LGG, collecting data on patient, tumor, and seizure characteristics between 2006 and 2017. We studied 79 patients in 2006 and 74 patients in 2017. There was no significant difference between the 2 groups in age at presentation, tumor location, or integrated pathological diagnosis. The numbers of complete or partial resections increased from 21.5% in 2006 to 60.8% in 2017 (P < .05). Five- and 10-year overall survival increased from 81.8% and 51.7% in 2006 to 100% and 95.8% in 2017 (P < .001); similarly, 5- and 10-year progression-free survival increased from 47.0% and 30.7% in 2006 to 93.1% and 68.7% in 2017. The proportion of patients with intractable epilepsy declined from 72.2% in 2006 to 43.2% in 2017 (P < .05). The neurosurgical morbidity rate was identical in both groups (11.8% in 2006 vs 11.1% in 2017). Management of LGG over the last 11 years has led to substantial improvements in survival and seizure control. This is most likely thanks to a change in surgical philosophy, with early resection now favored over watchful waiting where possible.
- 21 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 7 (2) , 196-201
Open AccessSeizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better
There has been a trend toward earlier and more aggressive resection for low-grade gliomas (LGGs). This study set out to compare seizure control and survival of adults with LGG seen in the same neuro-oncology clinic over 11 years and to determine whether a change in surgical philosophy has led to a corresponding improvement in outcomes. We conducted a retrospective analysis using case-note review of 153 adults with histologically verified or radiologically suspected LGG, collecting data on patient, tumor, and seizure characteristics between 2006 and 2017. We studied 79 patients in 2006 and 74 patients in 2017. There was no significant difference between the 2 groups in age at presentation, tumor location, or integrated pathological diagnosis. The numbers of complete or partial resections increased from 21.5% in 2006 to 60.8% in 2017 (P < .05). Five- and 10-year overall survival increased from 81.8% and 51.7% in 2006 to 100% and 95.8% in 2017 (P < .001); similarly, 5- and 10-year progression-free survival increased from 47.0% and 30.7% in 2006 to 93.1% and 68.7% in 2017. The proportion of patients with intractable epilepsy declined from 72.2% in 2006 to 43.2% in 2017 (P < .05). The neurosurgical morbidity rate was identical in both groups (11.8% in 2006 vs 11.1% in 2017). Management of LGG over the last 11 years has led to substantial improvements in survival and seizure control. This is most likely thanks to a change in surgical philosophy, with early resection now favored over watchful waiting where possible.